How does probenecid affect tigecycline absorption in the body?
Probenecid can change tigecycline absorption by inhibiting kidney transport pathways that normally take drugs out of the bloodstream. Tigecycline is handled by drug transporters involved in movement across tissues and into excretion routes; when probenecid blocks those transporters, drug concentrations can rise and exposure can shift. The net effect can be higher systemic exposure compared with tigecycline alone, reflecting reduced transporter-mediated clearance during absorption and distribution. [1]
Does this mean tigecycline gets absorbed faster or just stays in the body longer?
Because probenecid acts on transporter function rather than on stomach emptying or intestinal uptake in a direct, non-specific way, the practical consequence is usually described as altered systemic exposure (how much tigecycline reaches circulation) rather than clearly “faster” absorption. In other words, probenecid can increase or modify circulating tigecycline levels during the absorption/distribution phase by slowing transporter-mediated removal. [1]
What clinical implication does this have for dosing?
If probenecid increases tigecycline systemic exposure, it can increase the likelihood of dose-related adverse effects for a given tigecycline regimen. That means clinicians typically monitor tolerance and adjust only if exposure-related toxicity becomes a concern, guided by pharmacokinetic and safety data in the specific setting. [1]
What evidence is there for the mechanism?
The interaction is explained by transporter inhibition. Probenecid is used to inhibit certain transport processes involved in drug disposition, and tigecycline is a substrate for transport pathways that influence its movement and clearance. Blocking those pathways shifts tigecycline’s pharmacokinetics, including measures tied to absorption and early exposure. [1]
Source
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761120